Syngeneic Cell Line Reference Database

Browse or Search all
Taconic Biosciences
Resources

GO


Taconic Biosciences' inbred mice and GEMs on defined genetic backgrounds are widely used for syngeneic tumor studies, in which mouse tumor cells are engrafted into hosts from the same genetic background. Use the database of published references below to help you identify tumor cell lines and associated background strains in selecting the most appropriate model for your study.

New Mouse Model

Jh mouse of B6 background
Syngeneic studies without antibody interference

Learn More

White Paper

Syngeneic Mouse Models for Preclinical
Immuno-Oncology Research

Download Now
Filter by:

Cancer Type

Animal Model

Immunogenicity

Metastatic Potential

Cell Line

Citation
Hepatocellular Carcinoma C3H ++ Hca-F (HCa/16A3-F) World J. Gastroenterol. 2004 Feb 15;10(4):521-4
Carcinogenesis 2005 Mar;26(3):513-23
Mammary Adenocarcinoma FVB + DB-7(fvb2) Clin. Exp. Metastasis 2005;22(1):47-59
Melanoma DBA/2 Cloudman S91 (Clone M-3) Int. J. Radiat. Oncol. Biol. Phys. 1987 Nov;13(11):1725-33
Prostaglandins 1983 Sep;26(3):449-56
Mol. Ther. 2003 Apr;7(4):498-505
Br. J. Cancer 1988 Jan;57(1):64-9
Lymphoma Black 6 (B6NTac) C6VL J. Immunol. 2004 Jan 15;172(2):929-36
J. Immunol. 1982 Nov;129(5):2293-300
Fibrosarcoma Black 6 (B6NTac) MC57G J. Immunol. 2004 Jan 15;172(2):929-36
Melanoma Black 6 (B6NTac) -- ++ B16F10 Cancer Res. 1975 Jan;35(1):218-24
Cancer Res. 1999 Aug 15;59(16):4035-41
Nat. Med. 2016 Dec;22(12):1402-1410
Cancer Cell Int. 2013;13:75
Nature 2015 May 07;521(7550):99-104
Life Sci. 2002 Jan 04;70(7):791-8
Mol. Ther. 2003 Apr;7(4):498-505
PLoS ONE 2013;8(6):e66081
Hepatoma C3H ++ Hepatoma 134 (MH-134) Cancer Res. 1985 Apr;45(4):1532-5
Lymphosarcoma C3H 6C3HED Cancer Res. 1998 Jun 15;58(12):2594-600
Leukemia Black 6 (B6NTac) - RBL-5 J. Immunol. 1976 Oct;117(4):1267-74
J. Natl. Cancer Inst. 1978 Jan;60(1):239-42
J. Natl. Cancer Inst. 1977 Jun;58(6):1661-4
Lung Squamous Cell Carcinoma DBA/2 +++ KLN205 Cancer Res. 1978 Jul;38(7):2084-90
Cell Rep 2016 May 17;15(7):1505-13
Clin. Cancer Res. 2004 Jan 01;10(1 Pt 1):293-300
In Vitro 1980 Oct;16(10):884-92
Mammary Adenocarcinoma BALB/c --- SM1 Proc. Natl. Acad. Sci. U.S.A. 1998 Aug 18;95(17):10067-71
Cancer Res. 1992 Oct 15;52(20):5732-7
Bladder Carcinoma C3H + MBT-2 Urol. Res. 1997;25(3):179-82
Cancer Res. 1977 Aug;37(8 Pt 2):2918-29
Lymphoma BALB/c A20 (A-20) Blood 2009 Nov 12;114(20):4477-85
Adv Hematol 2012;2012:701704
Blood 2010 Jul 15;116(2):226-38
J. Immunol. 1979 Feb;122(2):549-54
Sarcoma BALB/c - Meth A Sarcoma (METH-A) Cell Prolif. 2001 Aug;34(4):211-22
Cell Prolif. 2003 Apr;36(2):87-100
Mol. Cell. Biol. 1989 Aug;9(8):3385-92
Proc. Natl. Acad. Sci. U.S.A. 1995 Mar 14;92(6):2219-23
Mammary Adenocarcinoma BALB/c +++ LM3 Carcinogenesis 2005 Mar;26(3):513-23
Int. J. Oncol. 1997 Sep;11(3):489-96
Lymphoma Black 6 (B6NTac) EL-4 Science 1971 Jan 08;171(3966):75-7
J. Immunol. 2004 Jan 15;172(2):929-36
J. Immunol. 2011 Apr 15;186(8):5004-11
Br. J. Cancer 1950 Dec;4(4):372-9
Prostate Adenocarcinoma Black 6 (B6NTac) TRAMP-C1D J. Biol. Chem. 2001 Apr 06;276(14):11204-13
Cancer Res. 1997 Aug 15;57(16):3325-30
Lymphosarcoma BALB/c LSTRA Leuk. Res. 2003 Apr;27(4):351-7
Cancer Res. 1968 Mar;28(3):434-9
EMBO J. 1982;1(12):1579-82
J. Immunol. 1976 Oct;117(4):1267-74
Mol. Cell. Biol. 1984 Dec;4(12):2705-13
Mammary Adenocarcinoma FVB H6O5 Oncogene 2012 May 24;31(21):2614-26
Proteomics 2010 Nov;10(21):3800-10
Plasmacytoma BALB/c J558 J. Exp. Med. 2001 Nov 05;194(9):1339-48
Lung Carcinoma Black 6 (B6NTac) +++ D122 (3LLD122) Int. J. Cancer 1984 Oct 15;34(4):567-73
Cancer Res. 1999 Aug 15;59(16):4035-41
Ovarian Carcinoma Black 6 (B6NTac) MOVCAR 5612 J Ovarian Res 2010 Oct 19;3:24
J. Biol. Chem. 2012 Aug 24;287(35):29873-86
Mammary Adenocarcinoma BALB/c D2F2 J. Leukoc. Biol. 1985 Nov;38(5):573-85
Br. J. Cancer 1992 May;65(5):641-8
Cancer Res. 2010 Oct 01;70(19):7431-41
Cancer Gene Ther. 2012 Apr;19(4):282-91
Ovarian Carcinoma Black 6 (B6NTac) MOVCAR 5447 J. Biol. Chem. 2012 Aug 24;287(35):29873-86
J Ovarian Res 2010 Oct 19;3:24
Colon Adenocarcinoma Black 6 (B6NTac) ++ MC-38 Carcinogenesis 2005 Mar;26(3):513-23
Cancer Res. 1975 Sep;35(9):2434-9
Clin. Exp. Immunol. 2009 Jul;157(1):128-38
Nat Commun 2017 Feb 21;8:14572
J. Natl. Cancer Inst. 1976 Apr;56(4):871-3
PLoS ONE 2016;11(9):e0161779
J. Immunother. 2010 Sep;33(7):697-705
Lymphoid Leukemia DBA/2 + L1210 J. Immunol. 2006 Jul 01;177(1):162-8
Immunology 2009 Sep;128(1 Suppl):e641-51
J. Natl. Cancer Inst. 1966 Mar;36(3):405-13, 415-21
Fibrosarcoma DBA/2 SaD2 J. Immunol. 1978 Sep;121(3):1007-9
Mammary Adenocarcinoma BALB/c TUBO J. Immunol. 2000 Nov 01;165(9):5133-42
Mol. Ther. 2013 Jan;21(1):91-100
Sarcoma 129S6 ++ F244 Immunology 2013 Jun;139(2):265-74
Cancer Immunol Res 2017 Feb;5(2):106-117
Oncoimmunology 2013 Jun 01;2(6):e24786
Lymphosarcoma BALB/c P1798 Mol. Cell. Endocrinol. 1980 Feb;17(2):95-102
Pancreatic Ductal Adenocarcinoma Black 6 (B6NTac) 6606PDA Eur Surg Res 2011;47(2):98-107
Cell Biosci 2015;5:51
BMC Cancer 2011 Jan 28;11:40
Reticulum Cell Sarcoma Black 6 (B6NTac) M5076 (M5) Eur. J. Cancer 1996 Oct;32A(11):2011-8
Cancer Res. 1981 Apr;41(4):1271-80
Plasmacytoma BALB/c ++ J558 Nat Commun 2017 Feb 21;8:14572
J. Natl. Cancer Inst. 1972 Sep;49(3):735-49
Carcinogenesis 2005 Mar;26(3):513-23
Prostate Adenocarcinoma Black 6 (B6NTac) TRAMP-C2 Cancer Res. 1997 Aug 15;57(16):3325-30
Mammary Adenocarcinoma DBA/2 + + T1699 Int. J. Cancer 1984 Jan 15;33(1):73-7
Lymphocytic Leukemia DBA/2 P1534 Int. Arch. Allergy Appl. Immunol. 1969;35(1):20-34
Glioma Black 6 (B6NTac) +++ GL261 (Glioma 261) Cancer Immunol. Immunother. 2015 Apr;64(4):447-57
Cancer Sci. 2006 Jun;97(6):546-53
PLoS ONE 2015;10(3):e0121314
Mammary Adenocarcinoma BALB/c ++ D2.0R Carcinogenesis 2005 Mar;26(3):513-23
Clin. Exp. Metastasis 1993 Jan;11(1):103-12
Mammary Adenocarcinoma C3H C3HBA Eur J Cancer 1975 Dec;11(12):891-901
Gastric Adenocarcinoma Black 6 (B6NTac) mGC8 BMC Cancer 2006 Mar 14;6:57
Leukemia C3H -- DA1-3b Leuk. Res. 1999 Apr;23(4):415-6
Blood 2004 Oct 01;104(7):2124-33
Gene Ther. 2000 Aug;7(15):1312-6
Lung Carcinoma Black 6 (B6NTac) +++ LL/2 Carcinogenesis 2005 Mar;26(3):513-23
Cancer Lett. 1980 Nov;11(1):63-73
Mesothelioma BALB/c AB12 Int. J. Cancer 1992 Dec 02;52(6):881-6
Oncol. Rep. 2012 Aug;28(2):707-13
Mol. Ther. 2002 Aug;6(2):210-8
Erythroleukemia Black 6 (B6NTac) FBL-3 J. Immunol. 1976 Oct;117(4):1267-74
J. Natl. Cancer Inst. 1978 Jan;60(1):239-42
Cancer Res. 1968 Mar;28(3):434-9
Lymphoma Black 6 (B6NTac) E.G7-OVA Cell 1988 Sep 09;54(6):777-85
J. Immunol. 2011 Apr 15;186(8):5004-11
Lung Carcinoma BALB/c ASB-XIV Cancer Treat Rep 1983 Dec;67(12):1061-5
Cancer Immunol Res 2015 Dec;3(12):1333-43
Hepatoma C3H + Hepatoma 134 (MH-134) J. Natl. Cancer Inst. 1981 Oct;67(4):947-56
Proc. Natl. Acad. Sci. U.S.A. 2004 Apr 06;101(14):4990-5
Mammary Adenocarcinoma FVB +++ Met-1(fvb2) Clin. Exp. Metastasis 2005;22(1):47-59
Lung Carcinoma Black 6 (B6NTac) ++ 3LL Cancer Lett. 1980 Nov;11(1):63-73
Blood 2010 Feb 18;115(7):1461-71
Clin. Cancer Res. 2007 Sep 15;13(18 Pt 1):5455-62
Cancer Res. 1999 Aug 15;59(16):4035-41
Osteosarcoma BALB/c +++ K7M2 Carcinogenesis 2005 Mar;26(3):513-23
Clin. Exp. Metastasis 2000;18(3):261-71
Ovarian Carcinoma Black 6 (B6NTac) ID8 (MOSEC) Anticancer Res. 26(4B):2785-9
Carcinogenesis 2000 Apr;21(4):585-91
J. Immunol. 2014 Nov 15;193(10):5327-37
Gynecol. Oncol. 2016 Aug;142(2):332-40
Gynecol. Oncol. 2008 Feb;108(2):385-94
Leukemia Black 6 (B6NTac) ++ RMA (RBL-5 subclone) Nature 2015 May 07;521(7550):99-104
J. Immunol. 2014 Feb 15;192(4):1577-86
J. Exp. Med. 1985 Dec 01;162(6):1745-59
Testicular Carcinoma Black 6 (B6NTac) M5480 J. Natl. Cancer Inst. 1975 Sep;55(3):623-31
Leukemia DBA/2 L-5178-Y J. Immunol. 2009 Feb 15;182(4):1940-53
Mutat. Res. 2017 Feb;814:1-6
Proc. Natl. Acad. Sci. U.S.A. 1996 Jun 25;93(13):6291-6
J. Immunol. 2004 Jul 15;173(2):1012-22
Colon Adenocarcinoma Black 6 (B6NTac) MC-38-CEA-1 Cancer Res. 1991 Jul 15;51(14):3657-62
Ovarian Carcinoma Black 6 (B6NTac) MOVCAR 5009 J Ovarian Res 2010 Oct 19;3:24
J. Biol. Chem. 2012 Aug 24;287(35):29873-86
Plasmacytoma C3H C1.18.4 (C1-18) Exp. Cell Res. 1970 Apr;60(1):61-77
Gastric Adenocarcinoma Black 6 (B6NTac) - 424GC BMC Cancer 2006 Mar 14;6:57
J Transl Med 2011 Aug 22;9:140
Myeloma Black 6 (B6NTac) 5T33 Br. J. Cancer 1992 Dec;66(6):1088-93
Bladder Carcinoma Black 6 (B6NTac) MB49 J. Immunol. 1997 Jul 01;159(1):351-9
Hepatocellular carcinoma Black 6 (B6NTac) Hep-55.1C Hepatol. Res. 2016 Aug 08;
Mol. Carcinog. 1992;6(2):148-58
Mammary Adenocarcinoma BALB/c +++ 4T1 Breast Cancer Res. 2000;2(5):331-4
Nature 2015 May 07;521(7550):99-104
Carcinogenesis 2005 Mar;26(3):513-23
Clin. Exp. Metastasis 1999 Mar;17(2):163-70
Proc. Natl. Acad. Sci. U.S.A. 2007 Oct 02;104(40):15735-40
Mammary Adenocarcinoma BALB/c MC4-L3 Cancer Res. 2001 Jan 01;61(1):293-302
Colon Carcinoma BALB/c +++ CT26 Nat Commun 2017 Feb 21;8:14572
Cancer Res. 1980 Jul;40(7):2142-6
Proc. Natl. Acad. Sci. U.S.A. 2005 Jan 11;102(2):419-24
Cancer Res. 2013 Apr 15;73(8):2493-504
PLoS ONE 2016;11(9):e0161779
Carcinogenesis 2005 Mar;26(3):513-23
Prostate Adenocarcinoma Black 6 (B6NTac) TRAMP-C1A Cancer Res. 1997 Aug 15;57(16):3325-30
J. Biol. Chem. 2001 Apr 06;276(14):11204-13
Mammary Adenocarcinoma Black 6 (B6NTac) ++ E0771 Cell Rep 2014 Mar 27;6(6):992-9
Dis Model Mech 2015 Mar;8(3):237-51
Proc. Soc. Exp. Biol. Med. 1951 Jun;77(2):358-62
Anticancer Res. 25(6B):3905-15
Nat Commun 2016 Jul 13;7:12258
Mammary Adenocarcinoma BALB/c MC4-L2 Cancer Res. 2001 Jan 01;61(1):293-302
Mammary Adenocarcinoma BALB/c ++ D2A1 Carcinogenesis 2005 Mar;26(3):513-23
Clin. Exp. Metastasis 1993 Jan;11(1):103-12
Mammary Adenocarcinoma BALB/c MC4-L1 Cancer Res. 2001 Jan 01;61(1):293-302
Mammary Adenocarcinoma BALB/c +++ 4T07 Int. J. Cancer 1991 Feb 01;47(3):466-72
Carcinogenesis 2005 Mar;26(3):513-23
Cancer Res. 1992 Mar 15;52(6):1399-405
Br. J. Cancer 1987 Nov;56(5):561-9
Squamous Cell Carcinoma C3H --- SCC-7 Cancer Lett. 2012 Apr 28;317(2):199-206
Cancer Res. 2016 Aug 15;76(16):4661-72
Br. J. Cancer 1982 Jul;46(1):109-16
Oncol Lett 2013 Dec;6(6):1799-1803
Lung Carcinoma BALB/c M109 (Madison Lung) In Vitro 1977 Apr;13(4):223-31
Cancer Treat Rep 1977 Nov;61(8):1459-70
Gastric Adenocarcinoma Black 6 (B6NTac) + mGC3 BMC Cancer 2006 Mar 14;6:57
J Transl Med 2011 Aug 22;9:140
Mammary Adenocarcinoma DBA/1 dbrB Proc. Soc. Exp. Biol. Med. 80(4):696-7
Prostate Adenocarcinoma Black 6 (B6NTac) ++ TRAMP-C1 Proc. Natl. Acad. Sci. U.S.A. 1997 Jul 22;94(15):8099-103
Cancer Res. 1997 Aug 15;57(16):3325-30
Acute Myeloid Leukemia Black 6 (B6NTac) C1498 J. Immunol. 1973 Jun;110(6):1470-5
Hepatocellular Carcinoma C3H - MH134 (MH134-TC) Cancer Immunol. Immunother. 1987;24(1):8-12
DNA Cell Biol. 2004 Sep;23(9):549-60
Cancer Res. 1985 Apr;45(4):1663-8
Fibrosarcoma Black 6 (B6NTac) MCA205 Cancer Immunol Res 2015 May;3(5):526-35
Neoplasia 2015 Aug;17(8):661-70
Oncoimmunology 2013 Jun 01;2(6):e24786
Lymphoma BALB/c PU5-1.8 (PU5-1R, TIB-61) J. Exp. Med. 1976 Jun 01;143(6):1528-33
Cancer Res. 1977 Feb;37(2):546-50
Colon Adenocarcinoma Black 6 (B6NTac) MC-38-CEA-2 Clin. Exp. Immunol. 2009 Jul;157(1):128-38
Cancer Res. 1991 Jul 15;51(14):3657-62
Mammary Adenocarcinoma Black 6 (B6NTac) Adenocarcinoma 755 (CA755) Int. J. Radiat. Oncol. Biol. Phys. 4(5-6):395-400
Oncotarget 2013 Oct;4(10):1829-35
Mammary Adenocarcinoma BALB/c MC4-L5 Cancer Res. 2001 Jan 01;61(1):293-302
Renal Adenocarcinoma BALB/c + ++ RenCa Cancer Res. 1986 Jul;46(7):3358-63
Carcinogenesis 2005 Mar;26(3):513-23
Mol. Ther. 2003 Apr;7(4):498-505
J. Immunol. 2006 Aug 15;177(4):2575-83
Mast Cell Leukemia DBA/2 ++ P815 J. Immunol. 1984 Jun;132(6):3218-25
Curr Protoc Immunol 2001 May;Chapter 20:Unit 20.4
J. Immunol. 2006 Jul 01;177(1):162-8
Differentiation 1986;32(2):157-64
Pancreatic Adenocarcinoma Black 6 (B6NTac) ++ Panc02 Clin Transl Sci 2008 Dec;1(3):228-39
Cancer Res. 1984 Feb;44(2):717-26
Eur Surg Res 2011;47(2):98-107
J. Immunother. 2010 Sep;33(7):697-705
J. Immunol. 2010 Oct 01;185(7):4063-71
J Vis Exp 2014 Sep 27;(91):51677
Int J Gastrointest Cancer 2001;29(1):37-46
Curr. Mol. Med. 2012 Mar;12(3):331-41
Leukemia BALB/c BCL1 Blood 2012 Jun 28;119(26):6344-53
Biol. Blood Marrow Transplant. 2014 Aug;20(8):1089-103
Colon Carcinoma BALB/c MC-26 (Colon 26, C-26) Cancer Res. 1975 Sep;35(9):2434-9
J. Nutr. 2005 Oct;135(10):2350-4
Proc. Natl. Acad. Sci. U.S.A. 2007 Jul 24;104(30):12457-61
Br. J. Cancer 2002 Aug 27;87(5):574-9
Mammary Adenocarcinoma C3H -- CaD2 Proc. Natl. Acad. Sci. U.S.A. 1977 Oct;74(10):4610-4
Cancer Lett. 1992 Jan 31;61(3):263-7
Pleiomorphic Cell Sarcoma Black 6 (B6NTac) - Lewis Sarcoma T241 Anticancer Res. 3(4):263-8
Cancer Res. 2011 Nov 01;71(21):6676-83
Plasmacytoma C3H + X5563 Exp. Cell Res. 1970 Apr;60(1):61-77
Cancer Immunol. Immunother. 1987;24(1):8-12
Osteogenic Sarcoma C3H HE 10734 Cancer Chemother Rep 1964 Jan;34:11-7
Lymphocytic Leukemia DBA/2 P388 Leukemia 1999 Oct;13(10):1592-600
Plasmacytoma BALB/c ADJ/PC6 Anticancer Drugs 2005 Jul;16(6):653-7
Immunology 1982 Nov;47(3):503-10
Colorectal carcinoma BALB/c - 51BLim10 Cancer Res. 1994 Dec 15;54(24):6477-83
Colon Adenocarcinoma BALB/c +++ LM17 Clin. Exp. Metastasis 1999;17(10):849-55
B cell Lymphoma C3H 38C13 Adv Hematol 2012;2012:701704
Eur. J. Immunol. 1977 Jul;7(7):413-7
Haematologica 2006 Feb;91(2):176-83
Mammary Adenocarcinoma FVB - Tgl-1 Gene Ther. 2006 Oct;13(19):1391-402
Cancer Res. 1998 May 01;58(9):1965-71
Mesothelioma Black 6 (B6NTac) AE17 Oncol. Rep. 2012 Aug;28(2):707-13
Mammary Adenocarcinoma BALB/c +++ 66C14 Breast Cancer Res. 2000;2(5):331-4
J. Cell. Biochem. 1988 Feb;36(2):129-36
Hepatocellular Carcinoma Black 6 (B6NTac) - Dt81Hepa1-6 PLoS ONE 2017;12(2):e0171215
Lymphosarcoma DBA/2 ++ +++ MDW3 Int. J. Cancer 1989 May 15;43(5):828-36
J. Natl. Cancer Inst. 1981 Jan;66(1):129-39
Int. J. Cancer 1984 Nov 15;34(5):709-16
Lymphosarcoma DBA/2 -- + MDAY-D2 Blood 2000 Jul 15;96(2):691-8
J. Cell Biol. 1995 Dec;131(6 Pt 2):1849-55
J. Natl. Cancer Inst. 1980 May;64(5):1221-30
Int. J. Cancer 1984 Nov 15;34(5):709-16
Prostate Adenocarcinoma Black 6 (B6NTac) - ++ RM-1 Prostate 2009 Nov 01;69(15):1613-23
J. Steroid Biochem. Mol. Biol. 1995 May;52(5):403-13
Nat Commun 2013;4:1795
Prostate Adenocarcinoma Black 6 (B6NTac) TRAMP-C3 Cancer Res. 1997 Aug 15;57(16):3325-30
Hepatoma C3H Hepatoma 129 Cancer Res. 1987 Dec 01;47(23):6216-9
Melanoma Black 6 (B6NTac) -- ++ B16 Clin. Cancer Res. 2007 Sep 15;13(18 Pt 1):5455-62
Cancer Lett. 1984 Aug;24(1):57-63
J. Natl. Cancer Inst. 1970 Oct;45(4):789-800
Carcinogenesis 2005 Mar;26(3):513-23
J. Cell Biol. 1969 Nov;43(2):263-74
Pancreatic Adenocarcinoma Black 6 (B6NTac) MT5 Gut 2016 Oct 21;
Squamous Cell Carcinoma Black 6 (B6NTac) ++ mEERL J. Virol. 2008 Mar;82(5):2493-500
Oncotarget 2016 Apr 26;7(17):24194-207
Head Neck 2015 Mar;37(3):327-35
Arch. Otolaryngol. Head Neck Surg. 2007 May;133(5):495-502
Lung Adenocarcinoma (transformed with HPV16) Black 6 (B6NTac) -- ++ TC-1 Nat. Med. 2016 Dec;22(12):1402-1410
Cancer Res. 1996 Jan 01;56(1):21-6
Proc. Natl. Acad. Sci. U.S.A. 2002 Dec 10;99(25):16232-6
Carcinogenesis 2005 Mar;26(3):513-23
Cancer Res. 2013 Apr 15;73(8):2493-504
Plasmacytoma BALB/c RPC5.4 Science 1971 Jan 08;171(3966):75-7
Mammary Carcinoma BALB/c EMT6 J. Natl. Cancer Inst. 1972 Sep;49(3):735-49
Close

Welcome! Tell us a little about yourself